The plaintiffs claim they were not adequately warned about the risks of developing brain tumors, including: Meningiomas: Though typically benign, meningiomas can cause significant symptoms and neurological problems such as headaches, vision issues, and cognitive impairments
In short: The medication and clinical experience are solid, and the variety of formats is a genuine differentiator
Taking into account the above-mentioned considerations on cost and safety aspects, oral small molecule agonists stimulating endogenous GLP-1 secretion by intestinal L-cells may offer a promising alternative for developing new treatments for Type 2 diabetes and obesity
How do oral GLP-1s work
The trial included a 24-week extension period at doses of 9 or 12 mg for about 500 adults with a BMI of 35 or greater, which is classified as severe obesity
That said, it has provided many people with a way to lose weight and improve their chronic conditions (like diabetes and fatty liver disease)